drugset / Trial / NCT07652125
RGL-270 + ICI in Advanced NSCLC
Recruiting
40 enrolled
Guangdong Association of Clinical Trials
Shanghai Regenelead Theraples,Co,Ltd. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a single-center, open-label, investigator-initiated clinical trial. It aims to evaluate the safety and tolerability of RGL-270 in combination with a PD-1/PD-L1 inhibitor, to assess immunogenicity, preliminary efficacy, and exploratory biomarkers and to observe the safety and effectiveness of PD-1/PD-L1 inhibitor monotherapy in advanced NSCLC subjects through a real-world observational cohort.
Timeline
- Start
- 2025-10-25
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RGL-270 | Messenger RNA (mRNA) | — | — |